Research Publications

Assessing the Safety of Early U.S. Commercial Application of Left Atrial Appendage Closure.

Saw J, Price MJ

Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.

Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL, CHAMPION Investigators

Antiplatelet and Anticoagulation Therapy in Percutaneous Coronary Intervention.

Angiolillo DJ, Price MJ

Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention.

Price MJ

Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device.

Enomoto Y, Gadiyaram VK, Gianni C, Horton RP, Trivedi C, Mohanty S, Di Biase L, Al-Ahmad A, Burkhardt JD, Narula A, Janczyk G, Price MJ, Afzal MR, Atoui M, Earnest M, Swarup V, Doshi SK, van der Zee S, Fisher R, Lakkireddy DR, Gibson DN, Natale A, Reddy VY

Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.

Sawlani NN, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL

Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings.

Selvaraj S, Bhatt DL, Stone GW, Gibson CM, Steg PG, Hamm CW, Price MJ, Deliargyris EN, Prats J, Mahaffey KW, White HD, Harrington RA, CHAMPION PHOENIX Investigators

Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update.

Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP

Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.

Abtan J, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, Price MJ, Abnousi F, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL, CHAMPION PHOENIX Investigators

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).

Cavender MA, Bhatt DL, Stone GW, White HD, Steg PG, Gibson CM, Hamm CW, Price MJ, Leonardi S, Prats J, Deliargyris EN, Mahaffey KW, Harrington RA, CHAMPION PHOENIX Investigators*